Matthew Durdy (CBO at Cell and Gene Therapy Catapult) leads a panel of cell and gene therapy manufacturing global experts to discuss the 2017 Automation Special Interest Group findings.The discussion goes on to explore how the industry is going to work together to standardise and close processes, all the while keeping an eye on the end game of commercialisation.
About this year's SIG (30-31 May 2018)
This year’s SIG continued this discussion and provided the industry with a dedicated time and space for long-term collaboration. There were 16 sessions you could choose from, including:
- Supply chain integration – what does your optimal solution look like and when to commit to it?
- Cell engineering – which tools, platforms or processes for genetically manipulating cells will win out in cell therapy?
- Future solution development – do we want to integrate or optimise first?